<DOC>
	<DOCNO>NCT00366899</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability immunogenicity 13-valent pneumococcal conjugate ( 13vPnC ) vaccine compare Prevenar ( 7vPnC ) , give concomitantly routine paediatric vaccination Italy .</brief_summary>
	<brief_title>Study Evaluating 13-valent Pneumococcal Conjugate Vaccine Infants</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Inclusion criterion : 1 . Aged 3 month ( 75 105 day ) time enrollment . 2 . Available entire study period whose parent ( ) /legal guardian ( ) could reach telephone . 3 . Healthy infant , determine medical history , physical examination , judgment investigator . 4 . Born great 32 week gestational age great 2000 gram . Regardless gestational age birth weight , subject must meet inclusion criterion number 3 . 5 . Parent ( ) /legal guardian ( ) able complete relevant study procedure study participation . Exclusion criterion : 1 . Previous vaccination license investigational pneumococcal vaccine . 2 . Previous vaccination Hib conjugate , diphtheria , tetanus , pertussis , polio , hepatitis B vaccine . 3 . A previous anaphylactic reaction vaccine vaccinerelated component . 4 . Contraindication vaccination Hib conjugate , diphtheria , tetanus , pertussis , polio , hepatitis B , pneumococcal vaccine . 5 . Bleeding diathesis condition associate prolonged bleeding time would contraindicate intramuscular injection . 6 . Known suspected immune deficiency suppression . 7 . History cultureproven invasive disease cause S pneumoniae Hib . 8 . Major know congenital malformation serious chronic disorder . 9 . Significant neurological disorder history seizure , include febrile seizure , significant stable evolve disorder , cerebral palsy , encephalopathy , hydrocephalus , significant disorder . Did include resolve syndrome due birth trauma Erb palsy . 10 . Receipt blood product gammaglobulin ( include hepatitis B immunoglobulin monoclonal antibody ; eg , SynagisÂ® [ MedImmune ] ) . 11 . Participation another investigational trial . Participation purely observational study acceptable . 12 . Infant direct descendant ( eg , child grandchild ) study site personnel .</criteria>
	<gender>All</gender>
	<minimum_age>75 Days</minimum_age>
	<maximum_age>105 Days</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Vaccine</keyword>
	<keyword>Infants</keyword>
</DOC>